Opitor-0
Based on 1 Customer Validation
Opitor-0 is a OPA1 GTPase inhibitor with an IC50 of 3.0 μM. Opitor-0 disrupts mitochondrial cristae structure and respiratory efficiency, induces mitochondrial fragmentation, enhances cBID-mediated cytochrome c release, and restores the sensitivity of triple-negative breast cancer (TNBC) cells to ABT-737 (HY-50907). Opitor-0 selectively reduces the migration and proliferation capacities of metastatic breast cancer cells, and induces cell death and apoptosis. Opitor-0 can be used in studies related to metastatic breast cancer and triple-negative breast cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.02%
- Formule: C30H25N5O2S
- Masse moléculaire:519.62
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Opitor-0 (50 μM; 6-24 h) induces mitochondrial fragmentation in MCF10A, MCF10AT1 and MCF10CA1h breast cells; it selectively reduces mitochondrial respiratory efficiency and ATP-coupled respiration in metastatic MCF10CA1h and MCF10CA1a breast cancer cells[1].
Opitor-0 (1-50 μM; 5 h) induces concentration-dependent mitochondrial fragmentation in mtYFP-expressing MEF cells and HeLa cells[2].
Opitor-0 (50 μM; 20 h) selectively impairs the migratory capacity of metastatic MCF10CA1h and MCF10CA1a breast cancer cells, without affecting non-metastatic MCF10A and MCF10AT1 breast cancer cells[1].
Opitor-0 (50 μM; 24 h) selectively reduces the proliferative capacity of highly metastatic MCF10CA1a breast cancer cells, without affecting non-metastatic MCF10A, MCF10AT1 or moderately metastatic MCF10CA1h breast cancer cells[1].
Opitor-0 (50 μM) does not induce cell death in any tested breast cancer cell lines after 24 h of treatment, but causes a small yet significant increase in the level of cell death in metastatic MCF10CA1h and MCF10CA1a breast cancer cells after 72 h of treatment, without affecting non-metastatic MCF10A and MCF10AT1 breast cancer cells[1].
Opitor-0 potently inhibits the GTPase activity of wild-type mini-rOpa1, with an IC50 of 3.0 μM[2].
Opitor-0 (25-125 μM; 30 min) potently enhances cBID-mediated cytochrome c release from purified mouse liver mitochondria[2].
Opitor-0 (5-100 μM; administered for 5 h after 12 h of preincubation with 10-20 μM ABT-737) exerts a strong synergistic effect with the Bcl-2 inhibitor ABT-737 (HY-50907) to induce caspase-dependent apoptosis in MDA-MB-231 triple-negative breast cancer cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MCF10A, MCF10AT1, MCF10CA1h, MCF10CA1a
-
Concentration:50 μM
-
Incubation Time:20 h
-
Result:Significantly reduced wound closure (increased remaining gap area) in metastatic MCF10CA1h and MCF10CA1a cells over 20 h.
Showed no significant effect on non-metastatic MCF10A and MCF10AT1 cells.
-
Cell Line:MCF10A, MCF10AT1, MCF10CA1h, MCF10CA1a
-
Concentration:50 μM
-
Incubation Time:24 h
-
Result:Significantly reduced the percentage of Phospho-Histone H3-positive nuclei in highly metastatic MCF10CA1a cells cultured in both Plasmax and DMEM.
Showed no significant effect on MCF10A, MCF10AT1, or MCF10CA1h cells.
-
Cell Line:MCF10A, MCF10AT1, MCF10CA1h, MCF10CA1a
-
Concentration:50 μM
-
Incubation Time:24 h; 72 h
-
Result:Did not induce significant cell death in any of the tested cell lines after 24 h treatment.
Induced a small but significant increase in Annexin V/PI-positive cells in metastatic MCF10CA1h and MCF10CA1a cells after 72 h treatment.
Showed no significant effect on non-metastatic MCF10A and MCF10AT1 cells after 72 h treatment.
Chemical Information
-
Appearance Solid
-
Masse moléculaire 519.62
-
Formule C30H25N5O2S
-
Color Off-white to yellow
-
SMILES
CC1=NN(C2=CC=CC=C2)C3=C1C=C(C(NC(C(N(N4CC5=CC=CC=C5)C6=CC=CC=C6)=O)=C4C)=O)S3
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvant et solubilité
DMSO : 35 mg/mL (67.36 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (282 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9245 mL | 9.6224 mL | 19.2448 mL | 48.1121 mL |
| 5 mM | 0.3849 mL | 1.9245 mL | 3.8490 mL | 9.6224 mL | |
| 10 mM | 0.1924 mL | 0.9622 mL | 1.9245 mL | 4.8112 mL | |
| 15 mM | 0.1283 mL | 0.6415 mL | 1.2830 mL | 3.2075 mL | |
| 20 mM | 0.0962 mL | 0.4811 mL | 0.9622 mL | 2.4056 mL | |
| 25 mM | 0.0770 mL | 0.3849 mL | 0.7698 mL | 1.9245 mL | |
| 30 mM | 0.0641 mL | 0.3207 mL | 0.6415 mL | 1.6037 mL | |
| 40 mM | 0.0481 mL | 0.2406 mL | 0.4811 mL | 1.2028 mL | |
| 50 mM | 0.0385 mL | 0.1924 mL | 0.3849 mL | 0.9622 mL | |
| 60 mM | 0.0321 mL | 0.1604 mL | 0.3207 mL | 0.8019 mL |
Opitor-0 Related Classifications
HY-177306 Related Classifications
Powered by Bioz